{"gene":"TSHR","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2011,"finding":"Crystal structure of the TSHR extracellular leucine-rich domain (amino acids 22-260) bound to a blocking-type human monoclonal autoantibody (K1-70) was solved at 1.9 Å resolution. K1-70 Fab binds the concave surface of the TSHR LRD with a large interface (2565 Ų), and mutation of contact residues influenced K1-70 activity, confirming the binding detail. K1-70 binds more N-terminally on the TSHR concave surface than the stimulating autoantibody M22 or TSH, clasping the surface in approximately the opposite orientation (~155° rotation) to M22, which may underlie its antagonist versus agonist functional difference.","method":"X-ray crystallography at 1.9 Å; site-directed mutagenesis of interface residues; functional cAMP assays to validate structural contacts","journal":"Journal of molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure with mutagenesis validation of contact residues and functional assays; multiple orthogonal methods in one rigorous study","pmids":["21247981"],"is_preprint":false},{"year":2006,"finding":"A low molecular weight (LMW) thienopyrimidine agonist (org41841) acts as a partial agonist for TSHR by binding within the transmembrane domain rather than the ectodomain. 3D molecular modeling predicted a binding pocket in clefts between TMHs 3, 4, 5, 6, 7 and extracellular loop 2, and chimeric receptor signaling studies provided experimental support. A key interaction between the conserved negatively charged E3.37 in the transmembrane domain and the amino group of org41841 was experimentally confirmed by mutagenesis.","method":"cAMP signaling assays with chimeric TSHR/LHCGR receptors; site-directed mutagenesis of E3.37; 3D molecular modeling and ligand docking","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis confirmed key receptor-ligand interaction, chimeric receptor experiments, and 3D model-guided predictions validated experimentally","pmids":["16488885"],"is_preprint":false},{"year":2010,"finding":"TSHR β-subunits (cleaved/truncated ectodomain fragments) dimerize with full-length TSHR, as demonstrated by co-immunoprecipitation and fluorescence resonance energy transfer. This interaction reduces full-length TSHR cell-surface expression and significantly decreases TSH-induced cAMP generation without altering basal constitutive cAMP levels. Truncated β-subunits also show faster internalization rates, contributing to reduced surface receptor availability and signaling.","method":"Co-immunoprecipitation; fluorescence resonance energy transfer (FRET); cAMP assays; flow cytometry for cell-surface expression","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP confirmed dimerization, FRET confirmed in vivo interaction, cAMP assays established functional consequence; single lab but multiple orthogonal methods","pmids":["20719860"],"is_preprint":false},{"year":2000,"finding":"Constitutively activating TSHR mutations (A623S and T632I) identified in thyroid carcinomas transform mouse 3T3 cells to a fully neoplastic phenotype (growth in soft agar; nude mouse tumorigenesis). The transformation is mediated by at least two pathways: the cAMP pathway via Gαs, and the Ras-dependent MAPK pathway via Gβγ and PI3Kγ. PI3Kγ signals to MAPK through a cascade involving a tyrosine kinase, Shc, Grb2, Sos, Ras, and Raf.","method":"Stable transfection of constitutively active TSHR mutants into 3T3 cells; soft agar colony formation; nude mouse tumor formation; pathway inhibitor experiments; signaling assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transformation assays with genetic constructs, multiple pathway readouts, single lab","pmids":["11039907"],"is_preprint":false},{"year":2007,"finding":"TSHR undergoes multiple post-translational modifications including N-glycosylation, phosphorylation, sialylation, and oligomerization/dimerization that modulate its function. Increased TSHR sialylation results in increased cell-surface expression. TSHR multimerization preferentially localizes in lipid rafts. In addition to coupling to Gαs and Gαq, TSHR also activates the MAPK pathway involving GRKs and β-arrestins.","method":"Biochemical characterization of glycosylation/sialylation mutants; lipid raft fractionation; MAPK pathway assays; review of multiple published studies","journal":"Trends in endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — synthesis of multiple experimental results; individual findings replicated across labs but this paper is a review; evidence for sialylation/surface expression and lipid raft localization from primary experiments","pmids":["17524661"],"is_preprint":false},{"year":2017,"finding":"GLIS3 acts downstream of TSH/TSHR signaling and is required for TSH/TSHR-mediated proliferation of thyroid follicular cells and biosynthesis of thyroid hormone. GLIS3 deficiency blocks TSH-mediated activation of the mTORC1/RPS6 pathway and reduces expression of cell division genes. ChIP-Seq showed GLIS3 directly binds promoters of NIS and PDS iodide transporter genes required for thyroid hormone biosynthesis.","method":"Conditional GLIS3 knockout mouse model; ChIP-Seq; promoter analysis; mTORC1/RPS6 pathway signaling assays; cell proliferation assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined phenotype, ChIP-Seq for direct binding, epistasis placing GLIS3 downstream of TSHR with multiple orthogonal methods","pmids":["29083325"],"is_preprint":false},{"year":2019,"finding":"TSHR activation by TSH in orbital fibroblasts stimulates proliferation through the PI3K/Akt signaling cascade and induces expression of miR-146a and miR-155. These microRNAs enhance proliferation by reducing expression of their targets ZNRF3 and PTEN, which normally limit cell proliferation. TSHR depletion by siRNA abrogated TSH-induced proliferation.","method":"TSHR-specific siRNA knockdown; BrdU incorporation proliferation assay; Western blot for PI3K/Akt activation; PI3K inhibitor (LY294002); qPCR for miRNA and gene expression","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with specific phenotypic readout, PI3K pathway inhibitor confirmation, miRNA target validation; single lab, multiple orthogonal methods","pmids":["31622470"],"is_preprint":false},{"year":2012,"finding":"TSHR expression is required for adipocyte differentiation; knockdown of TSHR in 3T3-L1 preadipocytes blocks their differentiation into mature adipocytes as assessed by Oil-Red-O staining for lipid accumulation and reduced PPAR-γ and ALBP mRNA expression.","method":"TSHR siRNA knockdown in 3T3-L1 cells; Oil-Red-O staining; RT-PCR for adipogenic markers (PPAR-γ, ALBP)","journal":"Lipids in health and disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean KD with defined cellular phenotype in a relevant model; single lab, two orthogonal readouts","pmids":["22289392"],"is_preprint":false},{"year":2010,"finding":"Tissue-specific knockout of TSHR in white adipose tissue (using Fabp4-Cre/loxP system) results in increased adipocyte size and decreased sensitivity to TSH-induced lipolysis (10-fold lower sensitivity to TSH in adipocytes from knockout mice). Catecholamine-induced lipolysis and insulin-mediated inhibition of lipolysis were unaltered, indicating TSHR specifically mediates TSH-dependent lipolytic signaling in adipocytes.","method":"Adipocyte-specific Cre-loxP conditional knockout; adipocyte size measurement; lipolysis assays with TSH, catecholamines, and insulin; thyroid gland histology","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with specific phenotypic readout and appropriate controls demonstrating pathway specificity; single lab, well-controlled study","pmids":["20152797"],"is_preprint":false},{"year":2018,"finding":"Liver-specific TSHR knockout (LT-KO) mice show reduced hepatic triglyceride and cholesterol content due to modified synthesis and catabolism of lipids, and decreased serum LDL-C levels, establishing a role for hepatic TSHR in liver lipid metabolism. Systemic energy metabolism was not affected by hepatic TSHR deletion.","method":"Liver-specific conditional TSHR KO (Cre/LoxP); measurement of hepatic and serum lipid levels; metabolic chamber studies","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional tissue-specific KO with defined metabolic phenotype; single lab, multiple readouts","pmids":["29421660"],"is_preprint":false},{"year":2015,"finding":"TSH/TSHR signaling suppresses fatty acid synthase (FASN) expression in mature adipocytes. TSH treatment activates PKA, phosphorylates CREB, and activates ERK1/2 and JNK. TSH-induced downregulation of FASN was partially abolished by PKA and ERK inhibition but not JNK inhibition, indicating FASN suppression is mediated by PKA and ERK pathways downstream of TSHR.","method":"TSH stimulation of mature adipocytes; Western blot for PKA activation, CREB phosphorylation, ERK and JNK; pathway inhibitors; RT-PCR and Western blot for FASN","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway inhibition with multiple signaling readouts; single lab, mechanistic follow-up","pmids":["25655684"],"is_preprint":false},{"year":2022,"finding":"In thyroid cancer cells, TSH binds TSHR coupled to Gα12/13 protein (rather than canonical GαS), which activates RhoA through interaction with leukemia-associated RhoA guanine exchange factor (LARG), leading to a pro-migration tumorigenic phenotype. PI3K/AKT/mTOR signaling enhances this noncanonical Gα12/13 pathway by increasing LARG levels, while simultaneously inhibiting GαS-dependent expression of thyroid-specific molecules and iodide uptake.","method":"Transcriptomic sequencing; Western blot for Gα12/13, RhoA, LARG, and downstream signals; cAMP assay; iodide uptake assay; migration assays","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — identification of noncanonical Gα12/13/RhoA/LARG coupling with multiple readouts; single lab","pmids":["34650915"],"is_preprint":false},{"year":1993,"finding":"Specific deletions (residues 295-306, 299-301, 387-395) and point mutations (Cys301Ser, Cys390Ser, Tyr385Phe, Tyr385Ala) in the TSHR extracellular domain markedly diminish the ability of the receptor to respond to blocking TSHRAbs but not stimulating TSHRAbs, mapping distinct epitopes for blocking versus stimulating autoantibodies. Three mutants (deletions of 295-306, 387-395, and C301S point mutation) were particularly useful for detecting stimulating TSHRAb activity in the presence of blocking antibodies.","method":"Site-directed mutagenesis and deletion constructs; cAMP assays in transfected cells; competitive binding assays with patient immunoglobulins","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with functional cAMP readout, patient serum validation; single lab, two orthogonal methods","pmids":["8100829"],"is_preprint":false},{"year":1993,"finding":"Antibodies directed against TSHR extracellular domain peptides block TSH-mediated activation of thyroid cells via two distinct mechanisms: one involving direct inhibition of TSH binding to the receptor (shown only by anti-ETSHR but not antipeptide antibodies in radioreceptor assay), and another involving a step downstream of TSH binding (shown by anti-peptide 3A and anti-2 antibodies blocking cAMP release and iodide uptake without inhibiting TSH binding).","method":"Antipeptide antibody characterization; cAMP release assay; iodide uptake assay; radioreceptor assay (RRA) for TSH binding inhibition","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays distinguishing two blocking mechanisms; single lab","pmids":["8103771"],"is_preprint":false},{"year":2009,"finding":"TSHR mutations R450H, T145I, and I661fs have distinct G-protein coupling defects. R450H-TSHR retains partial ability to transduce Gs-coupled signaling but has abrogated Gq-coupled signaling (dominant Gq coupling defect). T145I-TSHR retains partial ability to transduce both Gs and Gq pathways. I661fs-TSHR cannot transduce either Gs or Gq signaling.","method":"In vitro expression of mutant TSHR constructs; cAMP assay (Gs pathway); IP1/inositol phosphate assay (Gq pathway); phenotype correlation with radioiodine uptake in patients","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of mutant receptors with dual pathway (Gs and Gq) assays; single lab but rigorous mechanistic characterization with distinct pathway separation","pmids":["21677043"],"is_preprint":false},{"year":2005,"finding":"Orbital fibroblasts undergoing adipocytic differentiation show increased TSHR mRNA and protein expression. Differentiated orbital fibroblasts respond functionally to bovine TSH with increased cAMP production; a thyroid-inhibiting antibody (TBAb) inhibited this cAMP response and a thyroid-stimulating antibody (TSAb) stimulated cAMP production, demonstrating that TSHR expressed on differentiated orbital fibroblasts is functionally active and responds to autoantibodies.","method":"Real-time PCR for TSHR mRNA; immunocytochemistry for TSHR protein; cAMP radioimmunoassay after TSH and antibody stimulation","journal":"European journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cAMP assay confirming receptor signaling activity in orbital fibroblasts, with blocking and stimulating antibody controls; single lab","pmids":["15879364"],"is_preprint":false},{"year":2012,"finding":"PDGF-AB and PDGF-BB (but not PDGF-AA) stimulation increases TSHR expression on orbital fibroblasts. This enhanced TSHR expression amplifies the response to TSHR-stimulating autoantibodies, increasing production of IL-6, IL-8, CCL2, and hyaluronan. These effects were blocked by a TSHR blocking antibody (K1-70) and a cAMP inhibitor (H89), confirming they are mediated through TSHR signaling and cAMP.","method":"Flow cytometry for TSHR expression; ELISA for cytokine and hyaluronan production; pharmacological blocking with K1-70 antibody and H89 cAMP inhibitor","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific pathway blocking experiments with two inhibitors confirming TSHR/cAMP dependence; single lab, multiple orthogonal readouts","pmids":["22438231"],"is_preprint":false},{"year":2022,"finding":"TSH-TSHR signaling induces tumor PD-L1 expression through the TSHR-AC-PKA-JNK-c-JUN signaling pathway. TSHR inhibition reversed tumor immune evasion by inhibiting PD-L1 expression in tumor and myeloid cells and enhancing effector T cell activation in homograft mouse models.","method":"Transcriptomic sequencing; cellular signaling experiments; Western blot for pathway components; tumor immune evasion assays; homograft mouse model with TSHR inhibitor","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway identification with transcriptomics and cellular experiments, in vivo validation; single lab","pmids":["35101946"],"is_preprint":false},{"year":2024,"finding":"TSHR signaling promotes CD8+ T cell exhaustion through the PKA/CREB signaling pathway, upregulating immune checkpoint receptors PD-1 and TIM3. Conditional deletion of TSHR in CD8+ tumor-infiltrating lymphocytes improved effector differentiation and suppressed checkpoint receptor expression. CRC cells were found to secrete TSHR via exosomes, increasing TSHR levels in CD8+ T cells to promote immunosuppression.","method":"Conditional TSHR deletion in CD8+ T cells; RNA-sequencing; Western blotting; chromatin immunoprecipitation; luciferase reporter assay; immunofluorescence and flow cytometry; exosome isolation","journal":"Cancer communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined immune phenotype, multiple orthogonal methods identifying PKA/CREB pathway; single lab","pmids":["39285586"],"is_preprint":false},{"year":2021,"finding":"TSHR knockout or inhibition of palmitoylation-dependent TSHR activation alleviates TSH-induced apoptosis in Schwann cells exposed to high glucose/palmitic acid conditions. PA-induced TSHR palmitoylation was identified as a post-translational modification that enables TSH-mediated oxidative stress, mitochondrial dysfunction, and apoptosis in RSC96 Schwann cells.","method":"TSHR knockout in cell model; inhibition of TSHR palmitoylation; apoptosis assays; oxidative stress markers; mitochondrial function assays","journal":"Oxidative medicine and cellular longevity","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, palmitoylation mechanism inferred from inhibition experiments without direct biochemical characterization of the modification","pmids":["34804362"],"is_preprint":false},{"year":2008,"finding":"TSHR loss-of-function mutations (E34K, D403N, M527T, R46P, W488R) reduce or abolish TSH binding capacity and cAMP production in response to TSH. R46P and W488R completely abrogate both TSH binding and cAMP response. P27T has reduced cAMP response only at the highest TSH dose and is likely a polymorphism rather than a pathogenic mutation.","method":"Site-directed mutagenesis; expression in COS cells; cAMP assay; 125I-TSH binding assay; microchip flow cytometry for cell-surface expression","journal":"Clinical endocrinology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with binding and functional assays, multiple mutants characterized; single lab","pmids":["18727713"],"is_preprint":false},{"year":2008,"finding":"Novel activating TSHR mutations A623F and I635V in the transmembrane/intracellular domain cause constitutive activation of the cAMP pathway as demonstrated by elevated basal CRE-luciferase reporter activity in transfected cells compared to wild-type. This constitutive activation underlies toxic thyroid adenoma formation.","method":"Site-directed mutagenesis; CRE-luciferase reporter assay in transfected CO7 cells","journal":"European journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with luciferase reporter; single lab, single method per mutation","pmids":["18694911"],"is_preprint":false},{"year":2023,"finding":"Perfluorooctanoic acid (PFOA) disrupts TSH-activated cAMP signaling in thyroid cells by inhibiting TSHR mRNA expression and impairing TSHR N-glycosylation, thereby reducing CREB phosphorylation and downstream thyroid-specific gene transcription. These effects were rescued by the adenylyl cyclase activator forskolin, confirming TSHR-proximal disruption.","method":"RT-PCR and Western blot for TSHR and downstream gene expression; cAMP assay; CREB phosphorylation by Western blot; ER stress markers; forskolin rescue experiment","journal":"Environmental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — rescue experiment with forskolin confirms TSHR-level mechanism, N-glycosylation impairment identified with multiple readouts; single lab","pmids":["37827365"],"is_preprint":false},{"year":2011,"finding":"TSHR intron 1 disease-associated SNPs (rs179247 predisposing allele) lead to significantly reduced TSHR mRNA transcripts in thymus glands. Allele-specific transcript quantification in heterozygous individuals showed that the TSHR predisposing allele is expressed at lower levels than the protective allele in both thymic epithelial cells and thymocytes, suggesting that defective central T cell tolerance contributes to Graves' disease pathogenesis.","method":"Allele-specific transcript quantification by real-time PCR in thymic tissue; comparison of mRNA levels by genotype","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct quantification of allele-specific thymic expression replicated across donor samples; single lab but multiple tissue samples","pmids":["21642385"],"is_preprint":false},{"year":2015,"finding":"TSHR is functionally expressed in thymocytes, and Graves' disease stimulating autoantibodies (TSAbs) can stimulate thymocytes through this receptor, as confirmed by protein immunoblotting, qPCR, and functional signaling assays. TSHR expression is confined to maturing thymocytes.","method":"Protein immunoblotting; quantitative PCR; functional thymic TSHR stimulation assays with TSAbs","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional demonstration of thymic TSHR activity with multiple methods; single lab","pmids":["25801430"],"is_preprint":false},{"year":2008,"finding":"A novel germline activating TSHR mutation at codon 691 (Ile691Phe) located in the intracellular C-terminal domain causes autosomal dominant non-autoimmune hyperthyroidism across four generations. This is the first identified germline mutation in the intracellular C-terminal domain of TSHR.","method":"PCR sequencing of TSHR gene; linkage analysis to chromosome 14q24.2-31.3; in silico structural analysis","journal":"Journal of human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mutation identified by sequencing with genetic linkage but no in vitro functional characterization of receptor activity reported","pmids":["18306976"],"is_preprint":false},{"year":2009,"finding":"In vitro characterization of TSHR mutations G132R, A204V, D403N, and R450H confirmed loss-of-function for all four. R450H showed a founder effect in Japanese patients, being present in 6 of 9 mutant alleles identified.","method":"In vitro expression of mutant TSHR; cAMP assay for functional characterization; PCR sequencing in patient cohort","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro functional reconstitution with cAMP assay for multiple mutations; single lab","pmids":["19158199"],"is_preprint":false},{"year":2012,"finding":"TSHR gene transfection into dedifferentiated thyroid follicular carcinoma cells (dFTC-133) increased radioiodine uptake 2.9-fold and upregulated mRNA of thyroid differentiation markers NIS (4-fold), TPO (1.5-fold), Tg (2.2-fold), and TSHR itself (1.7-fold), demonstrating that TSHR expression is sufficient to promote redifferentiation and restore iodine uptake capacity.","method":"TSHR plasmid transfection; radioiodine (125I) uptake assay; real-time PCR for thyroid differentiation markers; immunofluorescence for TSHR localization","journal":"Nuclear medicine and biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene transfection with specific functional readout (iodine uptake) and multiple molecular markers; single lab","pmids":["22898315"],"is_preprint":false}],"current_model":"TSHR is a G protein-coupled receptor that canonically couples to Gαs to stimulate cAMP/PKA/CREB signaling in thyroid follicular cells, promoting thyroid hormone biosynthesis (requiring downstream transcription factor GLIS3), iodide uptake, and cell proliferation; it also couples to Gαq, Gα12/13 (activating RhoA/LARG in dedifferentiated cancer cells), and the MAPK pathway via GRKs/β-arrestins; its leucine-rich ectodomain binds TSH and autoantibodies with distinct orientations (structurally resolved by crystallography), while intramolecular cleavage produces α- and β-subunits whose dimerization modulates surface expression and signaling; extrathyroidally, TSHR regulates adipocyte differentiation, hepatic lipid metabolism, TSH-dependent lipolysis, and immune cell function (including CD8+ T cell exhaustion via PKA/CREB), and post-translational modifications including N-glycosylation, sialylation, phosphorylation, and palmitoylation further tune its cell-surface expression and signaling outputs."},"narrative":{"mechanistic_narrative":"TSHR is a G protein-coupled receptor whose leucine-rich ectodomain binds TSH and patient autoantibodies to drive cAMP signaling in thyroid follicular cells, controlling thyroid hormone biosynthesis, iodide uptake, and proliferation [PMID:21247981, PMID:22898315]. The canonical output couples through Gαs to cAMP, but receptor signaling is multiplexed: TSHR also engages Gαq and the Ras/MAPK pathway via Gβγ and PI3Kγ, and distinct loss-of-function mutations dissociate these arms (e.g., R450H selectively abrogates Gq while retaining partial Gs coupling) [PMID:11039907, PMID:21677043]. Downstream of TSHR, GLIS3 is required for TSH-driven proliferation and hormone synthesis, directly binding the NIS and PDS iodide-transporter promoters and licensing mTORC1/RPS6 activation [PMID:29083325]. Restoring TSHR in dedifferentiated thyroid carcinoma cells re-establishes iodide uptake and differentiation marker expression, while in thyroid cancer cells TSHR can instead couple to Gα12/13 to activate RhoA via LARG, producing a pro-migratory phenotype [PMID:34650915, PMID:22898315]. Activating mutations across the transmembrane and intracellular domains cause constitutive cAMP signaling underlying toxic adenoma and non-autoimmune hyperthyroidism, whereas loss-of-function mutations reduce TSH binding and cAMP output [PMID:11039907, PMID:18727713, PMID:18694911, PMID:18306976, PMID:19158199]. The receptor's structure and ligand pharmacology are defined: a 1.9 Å crystal structure shows the blocking autoantibody K1-70 clasping the LRD concave surface in roughly opposite orientation to stimulating antibodies, and a small-molecule agonist binds within the transmembrane helical bundle, explaining how agonists and antagonists act through distinct receptor surfaces [PMID:21247981, PMID:16488885, PMID:8100829]. TSHR function is tuned by post-translational modification — N-glycosylation, sialylation, phosphorylation, palmitoylation, and dimerization with cleaved β-subunits all modulate surface expression and signaling [PMID:20719860, PMID:17524661, PMID:37827365]. Extrathyroidally, TSHR is functionally expressed in orbital fibroblasts, adipocytes, hepatocytes, thymocytes, and immune cells, where it controls adipocyte differentiation and TSH-dependent lipolysis, hepatic lipid metabolism, orbital fibroblast proliferation and cytokine output, and tumor immune evasion through PKA/CREB- and JNK/c-JUN-driven checkpoint and PD-L1 induction [PMID:31622470, PMID:22289392, PMID:20152797, PMID:29421660, PMID:35101946, PMID:39285586].","teleology":[{"year":1993,"claim":"Establishing how thyroid-stimulating versus blocking autoantibodies act resolved that the ectodomain carries distinct functional epitopes and that some antibodies block at a step downstream of TSH binding.","evidence":"Deletion/point mutagenesis with cAMP assays and patient immunoglobulin binding; antipeptide antibodies tested in cAMP, iodide uptake, and radioreceptor assays","pmids":["8100829","8103771"],"confidence":"Medium","gaps":["Epitope maps inferred from mutant signaling, not structural complexes","Did not define the post-binding step blocked by downstream-acting antibodies"]},{"year":2000,"claim":"Constitutively activating carcinoma mutations were shown to be transforming, defining TSHR signaling as both cAMP/Gαs and Ras/MAPK driven via Gβγ and PI3Kγ.","evidence":"Stable expression of activating mutants in 3T3 cells with soft-agar, nude-mouse tumorigenesis, and pathway-inhibitor signaling assays","pmids":["11039907"],"confidence":"Medium","gaps":["MAPK cascade components inferred pharmacologically","Did not establish relative contribution of each arm to transformation in human thyroid"]},{"year":2006,"claim":"Discovery of a transmembrane-binding small-molecule agonist established that TSHR can be activated through the helical bundle independent of the ectodomain.","evidence":"cAMP assays with TSHR/LHCGR chimeras, E3.37 mutagenesis, and 3D docking","pmids":["16488885"],"confidence":"High","gaps":["Only partial agonism characterized","No experimental structure of the TMD-ligand complex"]},{"year":2007,"claim":"Characterization of post-translational modifications showed that sialylation, glycosylation, phosphorylation, dimerization, and lipid-raft localization tune receptor surface expression and signaling, including MAPK via GRKs/β-arrestins.","evidence":"Biochemical modification mutants, lipid-raft fractionation, and MAPK assays (review synthesizing primary data)","pmids":["17524661"],"confidence":"Medium","gaps":["Review-level synthesis rather than a single primary dataset","Quantitative contribution of each modification to signaling not resolved"]},{"year":2008,"claim":"Functional reconstitution of disease mutations defined the genotype-function map: loss-of-function mutations abolish TSH binding and cAMP, while activating TM/intracellular mutations drive constitutive cAMP, including a first C-terminal germline activating mutation.","evidence":"Site-directed mutagenesis with 125I-TSH binding, cAMP and CRE-luciferase assays, surface-expression flow cytometry; family linkage analysis for Ile691Phe","pmids":["18727713","18694911","18306976"],"confidence":"Medium","gaps":["Ile691Phe lacked in vitro functional confirmation","Surface vs. signaling defects not fully separated for all mutants"]},{"year":2009,"claim":"Dual-pathway assays demonstrated that individual mutations selectively impair Gs versus Gq coupling, showing TSHR signaling arms are genetically separable.","evidence":"In vitro mutant expression with cAMP (Gs) and IP1 (Gq) assays plus patient radioiodine correlation; cAMP characterization of additional loss-of-function mutants","pmids":["21677043","19158199"],"confidence":"High","gaps":["Physiological consequence of Gq-selective loss not fully defined","No structural basis for differential coupling"]},{"year":2010,"claim":"Studies of β-subunit dimerization and adipocyte-specific knockout established negative regulation by cleaved ectodomain fragments and a dedicated TSH-dependent lipolytic role in adipose tissue.","evidence":"Co-IP, FRET, cAMP and surface-expression assays for β-subunit dimers; Fabp4-Cre conditional knockout with lipolysis assays","pmids":["20719860","20152797"],"confidence":"High","gaps":["Source/regulation of β-subunit generation in vivo unclear","Downstream adipocyte lipolytic effectors not mapped"]},{"year":2012,"claim":"Extrathyroidal roles were extended: TSHR is required for adipocyte differentiation, restores differentiation/iodide uptake in dedifferentiated thyroid carcinoma, and amplifies PDGF-driven orbital fibroblast responses.","evidence":"siRNA knockdown in 3T3-L1 with adipogenic markers; TSHR transfection of dFTC-133 with radioiodine uptake; flow cytometry/ELISA with K1-70 and H89 blockade in orbital fibroblasts","pmids":["22289392","22898315","22438231"],"confidence":"Medium","gaps":["Mechanism linking TSHR to PPAR-γ induction not defined","Redifferentiation durability and in vivo relevance untested"]},{"year":2015,"claim":"TSH/TSHR signaling was shown to suppress lipogenic FASN via PKA and ERK, and functional thymic TSHR expression was demonstrated, linking the receptor to adipocyte lipid metabolism and central immune tolerance.","evidence":"TSH stimulation of adipocytes with pathway inhibitors and FASN readouts; immunoblot, qPCR and functional TSAb stimulation of thymocytes; earlier allele-specific thymic transcript quantification","pmids":["25655684","25801430","21642385","15879364"],"confidence":"Medium","gaps":["Causal link from thymic TSHR expression to tolerance not directly tested","Transcription factors mediating FASN suppression not identified"]},{"year":2017,"claim":"Genetic epistasis placed GLIS3 downstream of TSHR as a required effector for proliferation and hormone biosynthesis, providing a direct transcriptional link to iodide transporter genes.","evidence":"Conditional GLIS3 knockout mouse with ChIP-Seq, mTORC1/RPS6 signaling and proliferation assays","pmids":["29083325"],"confidence":"High","gaps":["How TSHR/cAMP signaling activates GLIS3 not defined","GLIS3 role outside thyroid follicular cells untested"]},{"year":2018,"claim":"Liver-specific knockout established a hepatic TSHR role in triglyceride, cholesterol, and LDL metabolism, extending the receptor's lipid-regulatory function beyond adipose tissue.","evidence":"Liver-specific Cre/loxP knockout with hepatic/serum lipid measurement and metabolic chamber studies","pmids":["29421660"],"confidence":"Medium","gaps":["Hepatic TSHR signaling pathway not mapped","Endogenous ligand driving hepatic signaling unclear"]},{"year":2019,"claim":"In orbital fibroblasts, TSHR activation was shown to drive proliferation through PI3K/Akt and a miR-146a/miR-155–ZNRF3/PTEN axis, defining a mechanism for orbital pathology.","evidence":"siRNA knockdown, BrdU proliferation, PI3K inhibitor, and miRNA/target qPCR","pmids":["31622470"],"confidence":"Medium","gaps":["miRNA-target effects validated by expression, not direct repression assays in this system","Single cell-type model"]},{"year":2022,"claim":"TSHR was shown to signal noncanonically through Gα12/13–LARG–RhoA to drive tumor cell migration and through PKA–JNK–c-JUN to induce PD-L1, recasting the receptor as a driver of cancer aggressiveness and immune evasion.","evidence":"Transcriptomics, immunoblotting, cAMP/iodide/migration assays for Gα12/13/RhoA; transcriptomics, signaling and homograft TSHR-inhibitor experiments for PD-L1","pmids":["34650915","35101946"],"confidence":"Medium","gaps":["Switch from Gαs to Gα12/13 coupling mechanism unresolved","Single-lab findings without independent replication"]},{"year":2024,"claim":"Conditional CD8+ T cell TSHR deletion demonstrated that TSHR signaling drives T cell exhaustion via PKA/CREB and that tumor exosomes deliver TSHR to T cells, establishing a tumor-immune mechanism.","evidence":"Conditional knockout, RNA-seq, ChIP, luciferase, flow cytometry and exosome isolation","pmids":["39285586"],"confidence":"Medium","gaps":["Exosomal TSHR transfer mechanism in patients untested","Single tumor type (CRC) examined"]},{"year":null,"claim":"How TSHR dynamically partitions among Gαs, Gαq, Gα12/13 and β-arrestin outputs across thyroidal and extrathyroidal tissues, and how this is set by ligand identity and post-translational state, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model linking ligand binding to differential G-protein selection","Tissue-specific signaling bias not systematically mapped","Palmitoylation mechanism characterized only by inhibition, not direct biochemistry"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,14,20]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0,1,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,11,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[20,21,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[17,18,24]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,9,10]}],"complexes":[],"partners":["TSH","GNAS","GNAQ","GNA12","GNA13","ARHGEF12","GLIS3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P16473","full_name":"Thyrotropin receptor","aliases":["Thyroid-stimulating hormone receptor","TSH-R"],"length_aa":764,"mass_kda":86.8,"function":"Receptor for the thyroid-stimulating hormone (TSH) or thyrotropin (PubMed:11847099, PubMed:12045258). Also acts as a receptor for the heterodimeric glycoprotein hormone (GPHA2:GPHB5) or thyrostimulin (PubMed:12045258). TSHR is coupled to G(s) proteins and mediates the activation of adenylate cyclase (PubMed:11847099, PubMed:35940205, PubMed:35940204). This leads to the generation of cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A (PKA). PKA subsequently phosphorylates downstream targets involved in thyroid hormone biosynthesis and secretion, including thyroid peroxidase (TPO) and the sodium/iodide symporter (NIS) (PubMed:27638195). Additionally, plays a central role in controlling thyroid cell metabolism (By similarity)","subcellular_location":"Cell membrane; Basolateral cell membrane","url":"https://www.uniprot.org/uniprotkb/P16473/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TSHR","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TSHR","total_profiled":1310},"omim":[{"mim_id":"612842","title":"RASD FAMILY, MEMBER 2; RASD2","url":"https://www.omim.org/entry/612842"},{"mim_id":"609893","title":"HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3","url":"https://www.omim.org/entry/609893"},{"mim_id":"609152","title":"HYPERTHYROIDISM, NONAUTOIMMUNE","url":"https://www.omim.org/entry/609152"},{"mim_id":"608173","title":"AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 1","url":"https://www.omim.org/entry/608173"},{"mim_id":"607358","title":"AUTOIMMUNE REGULATOR; AIRE","url":"https://www.omim.org/entry/607358"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"thyroid gland","ntpm":257.0}],"url":"https://www.proteinatlas.org/search/TSHR"},"hgnc":{"alias_symbol":["LGR3"],"prev_symbol":[]},"alphafold":{"accession":"P16473","domains":[{"cath_id":"1.20.1070.10","chopping":"416-697","consensus_level":"medium","plddt":83.1086,"start":416,"end":697}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16473","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16473-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16473-F1-predicted_aligned_error_v6.png","plddt_mean":74.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TSHR","jax_strain_url":"https://www.jax.org/strain/search?query=TSHR"},"sequence":{"accession":"P16473","fasta_url":"https://rest.uniprot.org/uniprotkb/P16473.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16473/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16473"}},"corpus_meta":[{"pmid":"12608932","id":"PMC_12608932","title":"TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients.","date":"2003","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12608932","citation_count":196,"is_preprint":false},{"pmid":"26429885","id":"PMC_26429885","title":"A brain circuit that synchronizes growth and maturation revealed through Dilp8 binding to Lgr3.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26429885","citation_count":141,"is_preprint":false},{"pmid":"26441350","id":"PMC_26441350","title":"Drosophila Lgr3 Couples Organ Growth with Maturation and Ensures Developmental Stability.","date":"2015","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/26441350","citation_count":140,"is_preprint":false},{"pmid":"16106256","id":"PMC_16106256","title":"Association of the TSHR gene with Graves' disease: the first disease specific locus.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/16106256","citation_count":135,"is_preprint":false},{"pmid":"26427660","id":"PMC_26427660","title":"Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26427660","citation_count":133,"is_preprint":false},{"pmid":"26510564","id":"PMC_26510564","title":"Dilp8 requires the neuronal relaxin receptor Lgr3 to couple growth to developmental timing.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26510564","citation_count":131,"is_preprint":false},{"pmid":"15115450","id":"PMC_15115450","title":"Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies.","date":"2004","source":"Acta ophthalmologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/15115450","citation_count":129,"is_preprint":false},{"pmid":"21247981","id":"PMC_21247981","title":"Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody.","date":"2011","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21247981","citation_count":101,"is_preprint":false},{"pmid":"19244275","id":"PMC_19244275","title":"Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19244275","citation_count":100,"is_preprint":false},{"pmid":"17803697","id":"PMC_17803697","title":"Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17803697","citation_count":98,"is_preprint":false},{"pmid":"25303483","id":"PMC_25303483","title":"Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25303483","citation_count":86,"is_preprint":false},{"pmid":"22289392","id":"PMC_22289392","title":"Role of extrathyroidal TSHR expression in adipocyte differentiation and its association with obesity.","date":"2012","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/22289392","citation_count":84,"is_preprint":false},{"pmid":"16488885","id":"PMC_16488885","title":"A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR).","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16488885","citation_count":82,"is_preprint":false},{"pmid":"19158199","id":"PMC_19158199","title":"TSHR mutations as a cause of congenital hypothyroidism in Japan: a population-based genetic epidemiology study.","date":"2009","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19158199","citation_count":77,"is_preprint":false},{"pmid":"27558136","id":"PMC_27558136","title":"Growth Coordination During Drosophila melanogaster Imaginal Disc Regeneration Is Mediated by Signaling Through the Relaxin Receptor Lgr3 in the Prothoracic Gland.","date":"2016","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27558136","citation_count":71,"is_preprint":false},{"pmid":"29083325","id":"PMC_29083325","title":"GLIS3 is indispensable for TSH/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29083325","citation_count":63,"is_preprint":false},{"pmid":"31622470","id":"PMC_31622470","title":"TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31622470","citation_count":59,"is_preprint":false},{"pmid":"8157713","id":"PMC_8157713","title":"Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype.","date":"1994","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8157713","citation_count":59,"is_preprint":false},{"pmid":"20926595","id":"PMC_20926595","title":"Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations.","date":"2010","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20926595","citation_count":58,"is_preprint":false},{"pmid":"33558728","id":"PMC_33558728","title":"Tumour-derived Dilp8/INSL3 induces cancer anorexia by regulating feeding neuropeptides via Lgr3/8 in the brain.","date":"2021","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/33558728","citation_count":57,"is_preprint":false},{"pmid":"21642385","id":"PMC_21642385","title":"Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21642385","citation_count":56,"is_preprint":false},{"pmid":"19438904","id":"PMC_19438904","title":"Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease.","date":"2009","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19438904","citation_count":55,"is_preprint":false},{"pmid":"29715504","id":"PMC_29715504","title":"The biology and evolution of the Dilp8-Lgr3 pathway: A relaxin-like pathway coupling tissue growth and developmental timing control.","date":"2018","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/29715504","citation_count":54,"is_preprint":false},{"pmid":"20083159","id":"PMC_20083159","title":"Genetics of thyroid autoimmunity and the role of the TSHR.","date":"2010","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20083159","citation_count":52,"is_preprint":false},{"pmid":"35101946","id":"PMC_35101946","title":"TSH-TSHR axis promotes tumor immune evasion.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35101946","citation_count":51,"is_preprint":false},{"pmid":"8100829","id":"PMC_8100829","title":"Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxedema, who have blocking TSHR antibodies.","date":"1993","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8100829","citation_count":46,"is_preprint":false},{"pmid":"18694911","id":"PMC_18694911","title":"Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.","date":"2008","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18694911","citation_count":46,"is_preprint":false},{"pmid":"20535589","id":"PMC_20535589","title":"Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.","date":"2010","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20535589","citation_count":44,"is_preprint":false},{"pmid":"26884206","id":"PMC_26884206","title":"Sex-specific regulation of Lgr3 in Drosophila neurons.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26884206","citation_count":43,"is_preprint":false},{"pmid":"36742308","id":"PMC_36742308","title":"A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36742308","citation_count":41,"is_preprint":false},{"pmid":"26361260","id":"PMC_26361260","title":"Mechanisms of Action of TSHR Autoantibodies.","date":"2015","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/26361260","citation_count":41,"is_preprint":false},{"pmid":"20152797","id":"PMC_20152797","title":"Tissue-specific knockout of TSHr in white adipose tissue increases adipocyte size and decreases TSH-induced lipolysis.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20152797","citation_count":41,"is_preprint":false},{"pmid":"34751400","id":"PMC_34751400","title":"CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.","date":"2022","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34751400","citation_count":40,"is_preprint":false},{"pmid":"8103771","id":"PMC_8103771","title":"Dual mechanism of perturbation of thyrotropin-mediated activation of thyroid cells by antibodies to the thyrotropin receptor (TSHR) and TSHR-derived peptides.","date":"1993","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8103771","citation_count":40,"is_preprint":false},{"pmid":"26873630","id":"PMC_26873630","title":"A domestication related mutation in the thyroid stimulating hormone receptor gene (TSHR) modulates photoperiodic response and reproduction in chickens.","date":"2016","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26873630","citation_count":39,"is_preprint":false},{"pmid":"22438231","id":"PMC_22438231","title":"PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22438231","citation_count":38,"is_preprint":false},{"pmid":"15879364","id":"PMC_15879364","title":"Evidence for protein and mRNA TSHr expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation.","date":"2005","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15879364","citation_count":36,"is_preprint":false},{"pmid":"17524661","id":"PMC_17524661","title":"Modulation of TSHR signaling by posttranslational modifications.","date":"2007","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/17524661","citation_count":33,"is_preprint":false},{"pmid":"21124799","id":"PMC_21124799","title":"Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21124799","citation_count":33,"is_preprint":false},{"pmid":"28127991","id":"PMC_28127991","title":"TSHR as a therapeutic target in Graves' disease.","date":"2017","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/28127991","citation_count":32,"is_preprint":false},{"pmid":"20718767","id":"PMC_20718767","title":"Novel TSHR mutations in consanguineous families with congenital nongoitrous hypothyroidism.","date":"2010","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20718767","citation_count":32,"is_preprint":false},{"pmid":"26361261","id":"PMC_26361261","title":"Genetics of Graves' Disease: Special Focus on the Role of TSHR Gene.","date":"2015","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/26361261","citation_count":31,"is_preprint":false},{"pmid":"24927793","id":"PMC_24927793","title":"Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.","date":"2014","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/24927793","citation_count":31,"is_preprint":false},{"pmid":"21707688","id":"PMC_21707688","title":"Molecular screening of the TSH receptor (TSHR) and thyroid peroxidase (TPO) genes in Korean patients with nonsyndromic congenital hypothyroidism.","date":"2011","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21707688","citation_count":30,"is_preprint":false},{"pmid":"39285586","id":"PMC_39285586","title":"Local TSH/TSHR signaling promotes CD8+ T cell exhaustion and immune evasion in colorectal carcinoma.","date":"2024","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/39285586","citation_count":29,"is_preprint":false},{"pmid":"9528975","id":"PMC_9528975","title":"The formation of thyrotropin receptor (TSHR) antibodies in a Graves' animal model requires the N-terminal segment of the TSHR extracellular domain.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9528975","citation_count":27,"is_preprint":false},{"pmid":"27637299","id":"PMC_27637299","title":"Next-generation sequencing analysis of TSHR in 384 Chinese subclinical congenital hypothyroidism (CH) and CH patients.","date":"2016","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27637299","citation_count":27,"is_preprint":false},{"pmid":"21677043","id":"PMC_21677043","title":"Nonclassic TSH resistance: TSHR mutation carriers with discrepantly high thyroidal iodine uptake.","date":"2011","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21677043","citation_count":26,"is_preprint":false},{"pmid":"34804362","id":"PMC_34804362","title":"TSH Combined with TSHR Aggravates Diabetic Peripheral Neuropathy by Promoting Oxidative Stress and Apoptosis in Schwann Cells.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34804362","citation_count":26,"is_preprint":false},{"pmid":"22876533","id":"PMC_22876533","title":"TSHR is the main causative locus in autosomal recessively inherited thyroid dysgenesis.","date":"2012","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/22876533","citation_count":25,"is_preprint":false},{"pmid":"21511239","id":"PMC_21511239","title":"Small molecule TSHR agonists and antagonists.","date":"2011","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/21511239","citation_count":24,"is_preprint":false},{"pmid":"25801430","id":"PMC_25801430","title":"Graves' disease TSHR-stimulating antibodies (TSAbs) induce the activation of immature thymocytes: a clue to the riddle of TSAbs generation?","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25801430","citation_count":24,"is_preprint":false},{"pmid":"29715101","id":"PMC_29715101","title":"Identification of Functional Thyroid Stimulating Hormone Receptor and TSHR Gene Mutations in Hepatocellular Carcinoma.","date":"2018","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29715101","citation_count":23,"is_preprint":false},{"pmid":"8864826","id":"PMC_8864826","title":"Yersinia enterocolitica envelope proteins that are crossreactive with the thyrotropin receptor (TSHR) also have B-cell mitogenic activity.","date":"1996","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/8864826","citation_count":23,"is_preprint":false},{"pmid":"37827365","id":"PMC_37827365","title":"Perfluorooctanoic acid disrupts thyroid-specific genes expression and regulation via the TSH-TSHR signaling pathway in thyroid cells.","date":"2023","source":"Environmental research","url":"https://pubmed.ncbi.nlm.nih.gov/37827365","citation_count":22,"is_preprint":false},{"pmid":"23386414","id":"PMC_23386414","title":"Examination of orbital tissues in murine models of Graves' disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues.","date":"2013","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/23386414","citation_count":22,"is_preprint":false},{"pmid":"29973096","id":"PMC_29973096","title":"Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.","date":"2018","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/29973096","citation_count":22,"is_preprint":false},{"pmid":"31356790","id":"PMC_31356790","title":"Mutation screening of the TSHR gene in 220 Chinese patients with congenital hypothyroidism.","date":"2019","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31356790","citation_count":21,"is_preprint":false},{"pmid":"25655684","id":"PMC_25655684","title":"TSH/TSHR Signaling Suppresses Fatty Acid Synthase (FASN) Expression in Adipocytes.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25655684","citation_count":21,"is_preprint":false},{"pmid":"29092890","id":"PMC_29092890","title":"Association between monoallelic TSHR mutations and congenital hypothyroidism: a statistical approach.","date":"2017","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29092890","citation_count":21,"is_preprint":false},{"pmid":"22496495","id":"PMC_22496495","title":"A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22496495","citation_count":21,"is_preprint":false},{"pmid":"25543543","id":"PMC_25543543","title":"TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy.","date":"2014","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25543543","citation_count":21,"is_preprint":false},{"pmid":"28455095","id":"PMC_28455095","title":"Next-generation sequencing of NKX2.1, FOXE1, PAX8, NKX2.5, and TSHR in 100 Chinese patients with congenital hypothyroidism and athyreosis.","date":"2017","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28455095","citation_count":21,"is_preprint":false},{"pmid":"22334716","id":"PMC_22334716","title":"Adoptive transfer of antithyrotropin receptor (TSHR) autoimmunity from TSHR knockout mice to athymic nude mice.","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22334716","citation_count":20,"is_preprint":false},{"pmid":"28319174","id":"PMC_28319174","title":"Simultaneous induction of Graves' hyperthyroidism and Graves' ophthalmopathy by TSHR genetic immunization in BALB/c mice.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28319174","citation_count":20,"is_preprint":false},{"pmid":"25061884","id":"PMC_25061884","title":"Association between polymorphisms in the TSHR gene and Graves' orbitopathy.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25061884","citation_count":19,"is_preprint":false},{"pmid":"18727713","id":"PMC_18727713","title":"Functional studies of new TSH receptor (TSHr) mutations identified in patients affected by hypothyroidism or isolated hyperthyrotrophinaemia.","date":"2008","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18727713","citation_count":19,"is_preprint":false},{"pmid":"31379878","id":"PMC_31379878","title":"Regulation of TSHR Expression in the Thyroid and Thymus May Contribute to TSHR Tolerance Failure in Graves' Disease Patients via Two Distinct Mechanisms.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31379878","citation_count":17,"is_preprint":false},{"pmid":"29344196","id":"PMC_29344196","title":"Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29344196","citation_count":17,"is_preprint":false},{"pmid":"29421660","id":"PMC_29421660","title":"Liver-specific deletion of TSHR inhibits hepatic lipid accumulation in mice.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29421660","citation_count":17,"is_preprint":false},{"pmid":"26519197","id":"PMC_26519197","title":"Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26519197","citation_count":17,"is_preprint":false},{"pmid":"20719860","id":"PMC_20719860","title":"Subunit interactions influence TSHR multimerization.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20719860","citation_count":16,"is_preprint":false},{"pmid":"11039907","id":"PMC_11039907","title":"Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11039907","citation_count":16,"is_preprint":false},{"pmid":"37690235","id":"PMC_37690235","title":"TSHR-based chimeric antigen receptor T cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37690235","citation_count":15,"is_preprint":false},{"pmid":"27762730","id":"PMC_27762730","title":"TSHR Gene Polymorphisms in the Enhancer Regions Are Most Strongly Associated with the Development of Graves' Disease, Especially Intractable Disease, and of Hashimoto's Disease.","date":"2016","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/27762730","citation_count":15,"is_preprint":false},{"pmid":"26260781","id":"PMC_26260781","title":"Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid.","date":"2015","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26260781","citation_count":15,"is_preprint":false},{"pmid":"30655754","id":"PMC_30655754","title":"Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30655754","citation_count":14,"is_preprint":false},{"pmid":"26053744","id":"PMC_26053744","title":"The Effect of a Mutation in the Thyroid Stimulating Hormone Receptor (TSHR) on Development, Behaviour and TH Levels in Domesticated Chickens.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26053744","citation_count":14,"is_preprint":false},{"pmid":"17608818","id":"PMC_17608818","title":"Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17608818","citation_count":14,"is_preprint":false},{"pmid":"37919223","id":"PMC_37919223","title":"Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.","date":"2023","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/37919223","citation_count":13,"is_preprint":false},{"pmid":"29973617","id":"PMC_29973617","title":"Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29973617","citation_count":13,"is_preprint":false},{"pmid":"34650915","id":"PMC_34650915","title":"Crosstalk Between Abnormal TSHR Signaling Activation and PTEN/PI3K in the Dedifferentiation of Thyroid Cancer Cells.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34650915","citation_count":13,"is_preprint":false},{"pmid":"18306976","id":"PMC_18306976","title":"A novel TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism.","date":"2008","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18306976","citation_count":13,"is_preprint":false},{"pmid":"32279226","id":"PMC_32279226","title":"Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.","date":"2020","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/32279226","citation_count":12,"is_preprint":false},{"pmid":"8981017","id":"PMC_8981017","title":"The gene for the thyrotropin receptor (TSHR) as a candidate gene for congenital hypothyroidism with thyroid dysgenesis.","date":"1996","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/8981017","citation_count":12,"is_preprint":false},{"pmid":"36142613","id":"PMC_36142613","title":"Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142613","citation_count":12,"is_preprint":false},{"pmid":"34751390","id":"PMC_34751390","title":"Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.","date":"2022","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34751390","citation_count":12,"is_preprint":false},{"pmid":"24690939","id":"PMC_24690939","title":"A deletion including exon 2 of the TSHR gene is associated with thyroid dysgenesis and severe congenital hypothyroidism.","date":"2014","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/24690939","citation_count":12,"is_preprint":false},{"pmid":"24845969","id":"PMC_24845969","title":"Controversial constitutive TSHR activity: patients, physiology, and in vitro characterization.","date":"2014","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/24845969","citation_count":11,"is_preprint":false},{"pmid":"20515734","id":"PMC_20515734","title":"Genetic defects, thyroid growth and malfunctions of the TSHR in pediatric patients.","date":"2010","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/20515734","citation_count":11,"is_preprint":false},{"pmid":"34172814","id":"PMC_34172814","title":"Functional differences between TSHR alleles associate with variation in spawning season in Atlantic herring.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34172814","citation_count":11,"is_preprint":false},{"pmid":"27525008","id":"PMC_27525008","title":"Upregulation of TSHR, TTF-1, and PAX8 in Nodular Goiter Is Associated with Iodine Deficiency in the Follicular Lumen.","date":"2016","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27525008","citation_count":11,"is_preprint":false},{"pmid":"21050930","id":"PMC_21050930","title":"Current standards, variations, and pitfalls for the determination of constitutive TSHR activity in vitro.","date":"2010","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/21050930","citation_count":11,"is_preprint":false},{"pmid":"38976794","id":"PMC_38976794","title":"PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [89Zr]Zr-TR1402.","date":"2024","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/38976794","citation_count":10,"is_preprint":false},{"pmid":"22898315","id":"PMC_22898315","title":"Re-induction of cell differentiation and (131)I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection.","date":"2012","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/22898315","citation_count":10,"is_preprint":false},{"pmid":"29093229","id":"PMC_29093229","title":"The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease.","date":"2017","source":"Acta medica Indonesiana","url":"https://pubmed.ncbi.nlm.nih.gov/29093229","citation_count":10,"is_preprint":false},{"pmid":"23592747","id":"PMC_23592747","title":"Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23592747","citation_count":10,"is_preprint":false},{"pmid":"39723207","id":"PMC_39723207","title":"Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39723207","citation_count":9,"is_preprint":false},{"pmid":"27231040","id":"PMC_27231040","title":"Association between TSHR gene polymorphism and the risk of Graves' disease: a meta-analysis.","date":"2015","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/27231040","citation_count":9,"is_preprint":false},{"pmid":"28195550","id":"PMC_28195550","title":"Novel germline mutation (Leu512Met) in the thyrotropin receptor gene (TSHR) leading to sporadic non-autoimmune hyperthyroidism.","date":"2017","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/28195550","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56121,"output_tokens":7637,"usd":0.141459,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17207,"output_tokens":5009,"usd":0.10563,"stage2_stop_reason":"end_turn"},"total_usd":0.247089,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of the TSHR extracellular leucine-rich domain (amino acids 22-260) bound to a blocking-type human monoclonal autoantibody (K1-70) was solved at 1.9 Å resolution. K1-70 Fab binds the concave surface of the TSHR LRD with a large interface (2565 Ų), and mutation of contact residues influenced K1-70 activity, confirming the binding detail. K1-70 binds more N-terminally on the TSHR concave surface than the stimulating autoantibody M22 or TSH, clasping the surface in approximately the opposite orientation (~155° rotation) to M22, which may underlie its antagonist versus agonist functional difference.\",\n      \"method\": \"X-ray crystallography at 1.9 Å; site-directed mutagenesis of interface residues; functional cAMP assays to validate structural contacts\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure with mutagenesis validation of contact residues and functional assays; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"21247981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A low molecular weight (LMW) thienopyrimidine agonist (org41841) acts as a partial agonist for TSHR by binding within the transmembrane domain rather than the ectodomain. 3D molecular modeling predicted a binding pocket in clefts between TMHs 3, 4, 5, 6, 7 and extracellular loop 2, and chimeric receptor signaling studies provided experimental support. A key interaction between the conserved negatively charged E3.37 in the transmembrane domain and the amino group of org41841 was experimentally confirmed by mutagenesis.\",\n      \"method\": \"cAMP signaling assays with chimeric TSHR/LHCGR receptors; site-directed mutagenesis of E3.37; 3D molecular modeling and ligand docking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis confirmed key receptor-ligand interaction, chimeric receptor experiments, and 3D model-guided predictions validated experimentally\",\n      \"pmids\": [\"16488885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TSHR β-subunits (cleaved/truncated ectodomain fragments) dimerize with full-length TSHR, as demonstrated by co-immunoprecipitation and fluorescence resonance energy transfer. This interaction reduces full-length TSHR cell-surface expression and significantly decreases TSH-induced cAMP generation without altering basal constitutive cAMP levels. Truncated β-subunits also show faster internalization rates, contributing to reduced surface receptor availability and signaling.\",\n      \"method\": \"Co-immunoprecipitation; fluorescence resonance energy transfer (FRET); cAMP assays; flow cytometry for cell-surface expression\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP confirmed dimerization, FRET confirmed in vivo interaction, cAMP assays established functional consequence; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"20719860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Constitutively activating TSHR mutations (A623S and T632I) identified in thyroid carcinomas transform mouse 3T3 cells to a fully neoplastic phenotype (growth in soft agar; nude mouse tumorigenesis). The transformation is mediated by at least two pathways: the cAMP pathway via Gαs, and the Ras-dependent MAPK pathway via Gβγ and PI3Kγ. PI3Kγ signals to MAPK through a cascade involving a tyrosine kinase, Shc, Grb2, Sos, Ras, and Raf.\",\n      \"method\": \"Stable transfection of constitutively active TSHR mutants into 3T3 cells; soft agar colony formation; nude mouse tumor formation; pathway inhibitor experiments; signaling assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transformation assays with genetic constructs, multiple pathway readouts, single lab\",\n      \"pmids\": [\"11039907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TSHR undergoes multiple post-translational modifications including N-glycosylation, phosphorylation, sialylation, and oligomerization/dimerization that modulate its function. Increased TSHR sialylation results in increased cell-surface expression. TSHR multimerization preferentially localizes in lipid rafts. In addition to coupling to Gαs and Gαq, TSHR also activates the MAPK pathway involving GRKs and β-arrestins.\",\n      \"method\": \"Biochemical characterization of glycosylation/sialylation mutants; lipid raft fractionation; MAPK pathway assays; review of multiple published studies\",\n      \"journal\": \"Trends in endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — synthesis of multiple experimental results; individual findings replicated across labs but this paper is a review; evidence for sialylation/surface expression and lipid raft localization from primary experiments\",\n      \"pmids\": [\"17524661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GLIS3 acts downstream of TSH/TSHR signaling and is required for TSH/TSHR-mediated proliferation of thyroid follicular cells and biosynthesis of thyroid hormone. GLIS3 deficiency blocks TSH-mediated activation of the mTORC1/RPS6 pathway and reduces expression of cell division genes. ChIP-Seq showed GLIS3 directly binds promoters of NIS and PDS iodide transporter genes required for thyroid hormone biosynthesis.\",\n      \"method\": \"Conditional GLIS3 knockout mouse model; ChIP-Seq; promoter analysis; mTORC1/RPS6 pathway signaling assays; cell proliferation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined phenotype, ChIP-Seq for direct binding, epistasis placing GLIS3 downstream of TSHR with multiple orthogonal methods\",\n      \"pmids\": [\"29083325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TSHR activation by TSH in orbital fibroblasts stimulates proliferation through the PI3K/Akt signaling cascade and induces expression of miR-146a and miR-155. These microRNAs enhance proliferation by reducing expression of their targets ZNRF3 and PTEN, which normally limit cell proliferation. TSHR depletion by siRNA abrogated TSH-induced proliferation.\",\n      \"method\": \"TSHR-specific siRNA knockdown; BrdU incorporation proliferation assay; Western blot for PI3K/Akt activation; PI3K inhibitor (LY294002); qPCR for miRNA and gene expression\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with specific phenotypic readout, PI3K pathway inhibitor confirmation, miRNA target validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31622470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TSHR expression is required for adipocyte differentiation; knockdown of TSHR in 3T3-L1 preadipocytes blocks their differentiation into mature adipocytes as assessed by Oil-Red-O staining for lipid accumulation and reduced PPAR-γ and ALBP mRNA expression.\",\n      \"method\": \"TSHR siRNA knockdown in 3T3-L1 cells; Oil-Red-O staining; RT-PCR for adipogenic markers (PPAR-γ, ALBP)\",\n      \"journal\": \"Lipids in health and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean KD with defined cellular phenotype in a relevant model; single lab, two orthogonal readouts\",\n      \"pmids\": [\"22289392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tissue-specific knockout of TSHR in white adipose tissue (using Fabp4-Cre/loxP system) results in increased adipocyte size and decreased sensitivity to TSH-induced lipolysis (10-fold lower sensitivity to TSH in adipocytes from knockout mice). Catecholamine-induced lipolysis and insulin-mediated inhibition of lipolysis were unaltered, indicating TSHR specifically mediates TSH-dependent lipolytic signaling in adipocytes.\",\n      \"method\": \"Adipocyte-specific Cre-loxP conditional knockout; adipocyte size measurement; lipolysis assays with TSH, catecholamines, and insulin; thyroid gland histology\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with specific phenotypic readout and appropriate controls demonstrating pathway specificity; single lab, well-controlled study\",\n      \"pmids\": [\"20152797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Liver-specific TSHR knockout (LT-KO) mice show reduced hepatic triglyceride and cholesterol content due to modified synthesis and catabolism of lipids, and decreased serum LDL-C levels, establishing a role for hepatic TSHR in liver lipid metabolism. Systemic energy metabolism was not affected by hepatic TSHR deletion.\",\n      \"method\": \"Liver-specific conditional TSHR KO (Cre/LoxP); measurement of hepatic and serum lipid levels; metabolic chamber studies\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional tissue-specific KO with defined metabolic phenotype; single lab, multiple readouts\",\n      \"pmids\": [\"29421660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TSH/TSHR signaling suppresses fatty acid synthase (FASN) expression in mature adipocytes. TSH treatment activates PKA, phosphorylates CREB, and activates ERK1/2 and JNK. TSH-induced downregulation of FASN was partially abolished by PKA and ERK inhibition but not JNK inhibition, indicating FASN suppression is mediated by PKA and ERK pathways downstream of TSHR.\",\n      \"method\": \"TSH stimulation of mature adipocytes; Western blot for PKA activation, CREB phosphorylation, ERK and JNK; pathway inhibitors; RT-PCR and Western blot for FASN\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway inhibition with multiple signaling readouts; single lab, mechanistic follow-up\",\n      \"pmids\": [\"25655684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In thyroid cancer cells, TSH binds TSHR coupled to Gα12/13 protein (rather than canonical GαS), which activates RhoA through interaction with leukemia-associated RhoA guanine exchange factor (LARG), leading to a pro-migration tumorigenic phenotype. PI3K/AKT/mTOR signaling enhances this noncanonical Gα12/13 pathway by increasing LARG levels, while simultaneously inhibiting GαS-dependent expression of thyroid-specific molecules and iodide uptake.\",\n      \"method\": \"Transcriptomic sequencing; Western blot for Gα12/13, RhoA, LARG, and downstream signals; cAMP assay; iodide uptake assay; migration assays\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — identification of noncanonical Gα12/13/RhoA/LARG coupling with multiple readouts; single lab\",\n      \"pmids\": [\"34650915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Specific deletions (residues 295-306, 299-301, 387-395) and point mutations (Cys301Ser, Cys390Ser, Tyr385Phe, Tyr385Ala) in the TSHR extracellular domain markedly diminish the ability of the receptor to respond to blocking TSHRAbs but not stimulating TSHRAbs, mapping distinct epitopes for blocking versus stimulating autoantibodies. Three mutants (deletions of 295-306, 387-395, and C301S point mutation) were particularly useful for detecting stimulating TSHRAb activity in the presence of blocking antibodies.\",\n      \"method\": \"Site-directed mutagenesis and deletion constructs; cAMP assays in transfected cells; competitive binding assays with patient immunoglobulins\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with functional cAMP readout, patient serum validation; single lab, two orthogonal methods\",\n      \"pmids\": [\"8100829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Antibodies directed against TSHR extracellular domain peptides block TSH-mediated activation of thyroid cells via two distinct mechanisms: one involving direct inhibition of TSH binding to the receptor (shown only by anti-ETSHR but not antipeptide antibodies in radioreceptor assay), and another involving a step downstream of TSH binding (shown by anti-peptide 3A and anti-2 antibodies blocking cAMP release and iodide uptake without inhibiting TSH binding).\",\n      \"method\": \"Antipeptide antibody characterization; cAMP release assay; iodide uptake assay; radioreceptor assay (RRA) for TSH binding inhibition\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays distinguishing two blocking mechanisms; single lab\",\n      \"pmids\": [\"8103771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TSHR mutations R450H, T145I, and I661fs have distinct G-protein coupling defects. R450H-TSHR retains partial ability to transduce Gs-coupled signaling but has abrogated Gq-coupled signaling (dominant Gq coupling defect). T145I-TSHR retains partial ability to transduce both Gs and Gq pathways. I661fs-TSHR cannot transduce either Gs or Gq signaling.\",\n      \"method\": \"In vitro expression of mutant TSHR constructs; cAMP assay (Gs pathway); IP1/inositol phosphate assay (Gq pathway); phenotype correlation with radioiodine uptake in patients\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of mutant receptors with dual pathway (Gs and Gq) assays; single lab but rigorous mechanistic characterization with distinct pathway separation\",\n      \"pmids\": [\"21677043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Orbital fibroblasts undergoing adipocytic differentiation show increased TSHR mRNA and protein expression. Differentiated orbital fibroblasts respond functionally to bovine TSH with increased cAMP production; a thyroid-inhibiting antibody (TBAb) inhibited this cAMP response and a thyroid-stimulating antibody (TSAb) stimulated cAMP production, demonstrating that TSHR expressed on differentiated orbital fibroblasts is functionally active and responds to autoantibodies.\",\n      \"method\": \"Real-time PCR for TSHR mRNA; immunocytochemistry for TSHR protein; cAMP radioimmunoassay after TSH and antibody stimulation\",\n      \"journal\": \"European journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cAMP assay confirming receptor signaling activity in orbital fibroblasts, with blocking and stimulating antibody controls; single lab\",\n      \"pmids\": [\"15879364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PDGF-AB and PDGF-BB (but not PDGF-AA) stimulation increases TSHR expression on orbital fibroblasts. This enhanced TSHR expression amplifies the response to TSHR-stimulating autoantibodies, increasing production of IL-6, IL-8, CCL2, and hyaluronan. These effects were blocked by a TSHR blocking antibody (K1-70) and a cAMP inhibitor (H89), confirming they are mediated through TSHR signaling and cAMP.\",\n      \"method\": \"Flow cytometry for TSHR expression; ELISA for cytokine and hyaluronan production; pharmacological blocking with K1-70 antibody and H89 cAMP inhibitor\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific pathway blocking experiments with two inhibitors confirming TSHR/cAMP dependence; single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"22438231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TSH-TSHR signaling induces tumor PD-L1 expression through the TSHR-AC-PKA-JNK-c-JUN signaling pathway. TSHR inhibition reversed tumor immune evasion by inhibiting PD-L1 expression in tumor and myeloid cells and enhancing effector T cell activation in homograft mouse models.\",\n      \"method\": \"Transcriptomic sequencing; cellular signaling experiments; Western blot for pathway components; tumor immune evasion assays; homograft mouse model with TSHR inhibitor\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway identification with transcriptomics and cellular experiments, in vivo validation; single lab\",\n      \"pmids\": [\"35101946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TSHR signaling promotes CD8+ T cell exhaustion through the PKA/CREB signaling pathway, upregulating immune checkpoint receptors PD-1 and TIM3. Conditional deletion of TSHR in CD8+ tumor-infiltrating lymphocytes improved effector differentiation and suppressed checkpoint receptor expression. CRC cells were found to secrete TSHR via exosomes, increasing TSHR levels in CD8+ T cells to promote immunosuppression.\",\n      \"method\": \"Conditional TSHR deletion in CD8+ T cells; RNA-sequencing; Western blotting; chromatin immunoprecipitation; luciferase reporter assay; immunofluorescence and flow cytometry; exosome isolation\",\n      \"journal\": \"Cancer communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined immune phenotype, multiple orthogonal methods identifying PKA/CREB pathway; single lab\",\n      \"pmids\": [\"39285586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TSHR knockout or inhibition of palmitoylation-dependent TSHR activation alleviates TSH-induced apoptosis in Schwann cells exposed to high glucose/palmitic acid conditions. PA-induced TSHR palmitoylation was identified as a post-translational modification that enables TSH-mediated oxidative stress, mitochondrial dysfunction, and apoptosis in RSC96 Schwann cells.\",\n      \"method\": \"TSHR knockout in cell model; inhibition of TSHR palmitoylation; apoptosis assays; oxidative stress markers; mitochondrial function assays\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, palmitoylation mechanism inferred from inhibition experiments without direct biochemical characterization of the modification\",\n      \"pmids\": [\"34804362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TSHR loss-of-function mutations (E34K, D403N, M527T, R46P, W488R) reduce or abolish TSH binding capacity and cAMP production in response to TSH. R46P and W488R completely abrogate both TSH binding and cAMP response. P27T has reduced cAMP response only at the highest TSH dose and is likely a polymorphism rather than a pathogenic mutation.\",\n      \"method\": \"Site-directed mutagenesis; expression in COS cells; cAMP assay; 125I-TSH binding assay; microchip flow cytometry for cell-surface expression\",\n      \"journal\": \"Clinical endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with binding and functional assays, multiple mutants characterized; single lab\",\n      \"pmids\": [\"18727713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Novel activating TSHR mutations A623F and I635V in the transmembrane/intracellular domain cause constitutive activation of the cAMP pathway as demonstrated by elevated basal CRE-luciferase reporter activity in transfected cells compared to wild-type. This constitutive activation underlies toxic thyroid adenoma formation.\",\n      \"method\": \"Site-directed mutagenesis; CRE-luciferase reporter assay in transfected CO7 cells\",\n      \"journal\": \"European journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with luciferase reporter; single lab, single method per mutation\",\n      \"pmids\": [\"18694911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Perfluorooctanoic acid (PFOA) disrupts TSH-activated cAMP signaling in thyroid cells by inhibiting TSHR mRNA expression and impairing TSHR N-glycosylation, thereby reducing CREB phosphorylation and downstream thyroid-specific gene transcription. These effects were rescued by the adenylyl cyclase activator forskolin, confirming TSHR-proximal disruption.\",\n      \"method\": \"RT-PCR and Western blot for TSHR and downstream gene expression; cAMP assay; CREB phosphorylation by Western blot; ER stress markers; forskolin rescue experiment\",\n      \"journal\": \"Environmental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rescue experiment with forskolin confirms TSHR-level mechanism, N-glycosylation impairment identified with multiple readouts; single lab\",\n      \"pmids\": [\"37827365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TSHR intron 1 disease-associated SNPs (rs179247 predisposing allele) lead to significantly reduced TSHR mRNA transcripts in thymus glands. Allele-specific transcript quantification in heterozygous individuals showed that the TSHR predisposing allele is expressed at lower levels than the protective allele in both thymic epithelial cells and thymocytes, suggesting that defective central T cell tolerance contributes to Graves' disease pathogenesis.\",\n      \"method\": \"Allele-specific transcript quantification by real-time PCR in thymic tissue; comparison of mRNA levels by genotype\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct quantification of allele-specific thymic expression replicated across donor samples; single lab but multiple tissue samples\",\n      \"pmids\": [\"21642385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TSHR is functionally expressed in thymocytes, and Graves' disease stimulating autoantibodies (TSAbs) can stimulate thymocytes through this receptor, as confirmed by protein immunoblotting, qPCR, and functional signaling assays. TSHR expression is confined to maturing thymocytes.\",\n      \"method\": \"Protein immunoblotting; quantitative PCR; functional thymic TSHR stimulation assays with TSAbs\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional demonstration of thymic TSHR activity with multiple methods; single lab\",\n      \"pmids\": [\"25801430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A novel germline activating TSHR mutation at codon 691 (Ile691Phe) located in the intracellular C-terminal domain causes autosomal dominant non-autoimmune hyperthyroidism across four generations. This is the first identified germline mutation in the intracellular C-terminal domain of TSHR.\",\n      \"method\": \"PCR sequencing of TSHR gene; linkage analysis to chromosome 14q24.2-31.3; in silico structural analysis\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mutation identified by sequencing with genetic linkage but no in vitro functional characterization of receptor activity reported\",\n      \"pmids\": [\"18306976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In vitro characterization of TSHR mutations G132R, A204V, D403N, and R450H confirmed loss-of-function for all four. R450H showed a founder effect in Japanese patients, being present in 6 of 9 mutant alleles identified.\",\n      \"method\": \"In vitro expression of mutant TSHR; cAMP assay for functional characterization; PCR sequencing in patient cohort\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro functional reconstitution with cAMP assay for multiple mutations; single lab\",\n      \"pmids\": [\"19158199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TSHR gene transfection into dedifferentiated thyroid follicular carcinoma cells (dFTC-133) increased radioiodine uptake 2.9-fold and upregulated mRNA of thyroid differentiation markers NIS (4-fold), TPO (1.5-fold), Tg (2.2-fold), and TSHR itself (1.7-fold), demonstrating that TSHR expression is sufficient to promote redifferentiation and restore iodine uptake capacity.\",\n      \"method\": \"TSHR plasmid transfection; radioiodine (125I) uptake assay; real-time PCR for thyroid differentiation markers; immunofluorescence for TSHR localization\",\n      \"journal\": \"Nuclear medicine and biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene transfection with specific functional readout (iodine uptake) and multiple molecular markers; single lab\",\n      \"pmids\": [\"22898315\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TSHR is a G protein-coupled receptor that canonically couples to Gαs to stimulate cAMP/PKA/CREB signaling in thyroid follicular cells, promoting thyroid hormone biosynthesis (requiring downstream transcription factor GLIS3), iodide uptake, and cell proliferation; it also couples to Gαq, Gα12/13 (activating RhoA/LARG in dedifferentiated cancer cells), and the MAPK pathway via GRKs/β-arrestins; its leucine-rich ectodomain binds TSH and autoantibodies with distinct orientations (structurally resolved by crystallography), while intramolecular cleavage produces α- and β-subunits whose dimerization modulates surface expression and signaling; extrathyroidally, TSHR regulates adipocyte differentiation, hepatic lipid metabolism, TSH-dependent lipolysis, and immune cell function (including CD8+ T cell exhaustion via PKA/CREB), and post-translational modifications including N-glycosylation, sialylation, phosphorylation, and palmitoylation further tune its cell-surface expression and signaling outputs.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TSHR is a G protein-coupled receptor whose leucine-rich ectodomain binds TSH and patient autoantibodies to drive cAMP signaling in thyroid follicular cells, controlling thyroid hormone biosynthesis, iodide uptake, and proliferation [#0, #27]. The canonical output couples through Gαs to cAMP, but receptor signaling is multiplexed: TSHR also engages Gαq and the Ras/MAPK pathway via Gβγ and PI3Kγ, and distinct loss-of-function mutations dissociate these arms (e.g., R450H selectively abrogates Gq while retaining partial Gs coupling) [#3, #14]. Downstream of TSHR, GLIS3 is required for TSH-driven proliferation and hormone synthesis, directly binding the NIS and PDS iodide-transporter promoters and licensing mTORC1/RPS6 activation [#5]. Restoring TSHR in dedifferentiated thyroid carcinoma cells re-establishes iodide uptake and differentiation marker expression, while in thyroid cancer cells TSHR can instead couple to Gα12/13 to activate RhoA via LARG, producing a pro-migratory phenotype [#11, #27]. Activating mutations across the transmembrane and intracellular domains cause constitutive cAMP signaling underlying toxic adenoma and non-autoimmune hyperthyroidism, whereas loss-of-function mutations reduce TSH binding and cAMP output [#3, #20, #21, #25, #26]. The receptor's structure and ligand pharmacology are defined: a 1.9 Å crystal structure shows the blocking autoantibody K1-70 clasping the LRD concave surface in roughly opposite orientation to stimulating antibodies, and a small-molecule agonist binds within the transmembrane helical bundle, explaining how agonists and antagonists act through distinct receptor surfaces [#0, #1, #12]. TSHR function is tuned by post-translational modification — N-glycosylation, sialylation, phosphorylation, palmitoylation, and dimerization with cleaved β-subunits all modulate surface expression and signaling [#2, #4, #22]. Extrathyroidally, TSHR is functionally expressed in orbital fibroblasts, adipocytes, hepatocytes, thymocytes, and immune cells, where it controls adipocyte differentiation and TSH-dependent lipolysis, hepatic lipid metabolism, orbital fibroblast proliferation and cytokine output, and tumor immune evasion through PKA/CREB- and JNK/c-JUN-driven checkpoint and PD-L1 induction [#6, #7, #8, #9, #17, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing how thyroid-stimulating versus blocking autoantibodies act resolved that the ectodomain carries distinct functional epitopes and that some antibodies block at a step downstream of TSH binding.\",\n      \"evidence\": \"Deletion/point mutagenesis with cAMP assays and patient immunoglobulin binding; antipeptide antibodies tested in cAMP, iodide uptake, and radioreceptor assays\",\n      \"pmids\": [\"8100829\", \"8103771\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Epitope maps inferred from mutant signaling, not structural complexes\", \"Did not define the post-binding step blocked by downstream-acting antibodies\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Constitutively activating carcinoma mutations were shown to be transforming, defining TSHR signaling as both cAMP/Gαs and Ras/MAPK driven via Gβγ and PI3Kγ.\",\n      \"evidence\": \"Stable expression of activating mutants in 3T3 cells with soft-agar, nude-mouse tumorigenesis, and pathway-inhibitor signaling assays\",\n      \"pmids\": [\"11039907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MAPK cascade components inferred pharmacologically\", \"Did not establish relative contribution of each arm to transformation in human thyroid\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery of a transmembrane-binding small-molecule agonist established that TSHR can be activated through the helical bundle independent of the ectodomain.\",\n      \"evidence\": \"cAMP assays with TSHR/LHCGR chimeras, E3.37 mutagenesis, and 3D docking\",\n      \"pmids\": [\"16488885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Only partial agonism characterized\", \"No experimental structure of the TMD-ligand complex\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Characterization of post-translational modifications showed that sialylation, glycosylation, phosphorylation, dimerization, and lipid-raft localization tune receptor surface expression and signaling, including MAPK via GRKs/β-arrestins.\",\n      \"evidence\": \"Biochemical modification mutants, lipid-raft fractionation, and MAPK assays (review synthesizing primary data)\",\n      \"pmids\": [\"17524661\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level synthesis rather than a single primary dataset\", \"Quantitative contribution of each modification to signaling not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Functional reconstitution of disease mutations defined the genotype-function map: loss-of-function mutations abolish TSH binding and cAMP, while activating TM/intracellular mutations drive constitutive cAMP, including a first C-terminal germline activating mutation.\",\n      \"evidence\": \"Site-directed mutagenesis with 125I-TSH binding, cAMP and CRE-luciferase assays, surface-expression flow cytometry; family linkage analysis for Ile691Phe\",\n      \"pmids\": [\"18727713\", \"18694911\", \"18306976\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ile691Phe lacked in vitro functional confirmation\", \"Surface vs. signaling defects not fully separated for all mutants\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Dual-pathway assays demonstrated that individual mutations selectively impair Gs versus Gq coupling, showing TSHR signaling arms are genetically separable.\",\n      \"evidence\": \"In vitro mutant expression with cAMP (Gs) and IP1 (Gq) assays plus patient radioiodine correlation; cAMP characterization of additional loss-of-function mutants\",\n      \"pmids\": [\"21677043\", \"19158199\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of Gq-selective loss not fully defined\", \"No structural basis for differential coupling\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Studies of β-subunit dimerization and adipocyte-specific knockout established negative regulation by cleaved ectodomain fragments and a dedicated TSH-dependent lipolytic role in adipose tissue.\",\n      \"evidence\": \"Co-IP, FRET, cAMP and surface-expression assays for β-subunit dimers; Fabp4-Cre conditional knockout with lipolysis assays\",\n      \"pmids\": [\"20719860\", \"20152797\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source/regulation of β-subunit generation in vivo unclear\", \"Downstream adipocyte lipolytic effectors not mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extrathyroidal roles were extended: TSHR is required for adipocyte differentiation, restores differentiation/iodide uptake in dedifferentiated thyroid carcinoma, and amplifies PDGF-driven orbital fibroblast responses.\",\n      \"evidence\": \"siRNA knockdown in 3T3-L1 with adipogenic markers; TSHR transfection of dFTC-133 with radioiodine uptake; flow cytometry/ELISA with K1-70 and H89 blockade in orbital fibroblasts\",\n      \"pmids\": [\"22289392\", \"22898315\", \"22438231\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking TSHR to PPAR-γ induction not defined\", \"Redifferentiation durability and in vivo relevance untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"TSH/TSHR signaling was shown to suppress lipogenic FASN via PKA and ERK, and functional thymic TSHR expression was demonstrated, linking the receptor to adipocyte lipid metabolism and central immune tolerance.\",\n      \"evidence\": \"TSH stimulation of adipocytes with pathway inhibitors and FASN readouts; immunoblot, qPCR and functional TSAb stimulation of thymocytes; earlier allele-specific thymic transcript quantification\",\n      \"pmids\": [\"25655684\", \"25801430\", \"21642385\", \"15879364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link from thymic TSHR expression to tolerance not directly tested\", \"Transcription factors mediating FASN suppression not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Genetic epistasis placed GLIS3 downstream of TSHR as a required effector for proliferation and hormone biosynthesis, providing a direct transcriptional link to iodide transporter genes.\",\n      \"evidence\": \"Conditional GLIS3 knockout mouse with ChIP-Seq, mTORC1/RPS6 signaling and proliferation assays\",\n      \"pmids\": [\"29083325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TSHR/cAMP signaling activates GLIS3 not defined\", \"GLIS3 role outside thyroid follicular cells untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Liver-specific knockout established a hepatic TSHR role in triglyceride, cholesterol, and LDL metabolism, extending the receptor's lipid-regulatory function beyond adipose tissue.\",\n      \"evidence\": \"Liver-specific Cre/loxP knockout with hepatic/serum lipid measurement and metabolic chamber studies\",\n      \"pmids\": [\"29421660\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hepatic TSHR signaling pathway not mapped\", \"Endogenous ligand driving hepatic signaling unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"In orbital fibroblasts, TSHR activation was shown to drive proliferation through PI3K/Akt and a miR-146a/miR-155–ZNRF3/PTEN axis, defining a mechanism for orbital pathology.\",\n      \"evidence\": \"siRNA knockdown, BrdU proliferation, PI3K inhibitor, and miRNA/target qPCR\",\n      \"pmids\": [\"31622470\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"miRNA-target effects validated by expression, not direct repression assays in this system\", \"Single cell-type model\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"TSHR was shown to signal noncanonically through Gα12/13–LARG–RhoA to drive tumor cell migration and through PKA–JNK–c-JUN to induce PD-L1, recasting the receptor as a driver of cancer aggressiveness and immune evasion.\",\n      \"evidence\": \"Transcriptomics, immunoblotting, cAMP/iodide/migration assays for Gα12/13/RhoA; transcriptomics, signaling and homograft TSHR-inhibitor experiments for PD-L1\",\n      \"pmids\": [\"34650915\", \"35101946\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Switch from Gαs to Gα12/13 coupling mechanism unresolved\", \"Single-lab findings without independent replication\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Conditional CD8+ T cell TSHR deletion demonstrated that TSHR signaling drives T cell exhaustion via PKA/CREB and that tumor exosomes deliver TSHR to T cells, establishing a tumor-immune mechanism.\",\n      \"evidence\": \"Conditional knockout, RNA-seq, ChIP, luciferase, flow cytometry and exosome isolation\",\n      \"pmids\": [\"39285586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Exosomal TSHR transfer mechanism in patients untested\", \"Single tumor type (CRC) examined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TSHR dynamically partitions among Gαs, Gαq, Gα12/13 and β-arrestin outputs across thyroidal and extrathyroidal tissues, and how this is set by ligand identity and post-translational state, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model linking ligand binding to differential G-protein selection\", \"Tissue-specific signaling bias not systematically mapped\", \"Palmitoylation mechanism characterized only by inhibition, not direct biochemistry\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 14, 20]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0, 1, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 11, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [20, 21, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [17, 18, 24]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 9, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TSH\", \"GNAS\", \"GNAQ\", \"GNA12\", \"GNA13\", \"ARHGEF12\", \"GLIS3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}